Viking Therapeutics, Inc. Stock News

Viking Therapeutics offers a de-risked, asymmetric investment opportunity in the GLP-1 weight-loss drug market, trading below its risk-adjusted potential. VKTX's injectable and oral VK2735 both met Phase 2 endpoints, with discontinuation issues in the oral form likely fixable through slower titration and different dosing. Strong cash reserves, committed manufacturing partner, and a diversified ...

Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize on the trend.

Viking Therapeutics trades at yearly lows despite being ahead of recently acquired competitor Metsera in the weight-loss drug race. The Metsera deal suggests up to 150% upside to Viking, especially when compared to Pfizer's $7.2 billion buyout price, including milestone CVRs. VKTX's oral and injectable weight-loss drugs show promising results, with Phase 3 trials already ongoing and potential t...

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 11:20 AM EDT Company Participants Brian Lian - President, CEO & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2023 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Brian Lian - President and CEO Greg Zante - CFO Stephanie Diaz - Manager of IR Conference Call Participants Joon Lee - Truist Steven Seedhouse - Raymond James Jay Olson - Oppenheimer. Naz Rahman - Maxim Group.

The late investing legend Charlie Munger talked about a "fat-pitch strategy," a baseball analogy about waiting for a big, no-brainer opportunity you can take advantage of. When you get that fat pitch, it's a chance to get a home run.

Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.

It's been a tough year for healthcare stocks. The broader industry has underperformed the market this year, at least as judged by major healthcare-focused exchange-traded funds, such as the Vanguard Health Care ETF.